

DCE-MRI Provides Evidence for Vascular Effects of AMG 386, a First-in-Class Anti-angiogenic Peptibody that Specifically Inhibits Interaction of Angiopoietins-1 and -2 with Tie-2

Y. C. Hwang¹, E. Ashton², L. Rosen³, R. Herbst⁴, J. Silverman⁵, N. Le¹, E. Rasmussen¹, J. Oliner¹, J. Leal⁶, R. Radinsky¹, J-R. Sun¹, J. Evelhoch¹, and E. Jackson⁴

¹Amgen Inc., Thousand Oaks, CA, United States, ²VirtualScopics Inc., Rochester, NY, United States, ³Premiere Oncology, Santa Monica, CA, United States, ⁴The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States, ⁵Landmark Imaging, Los Angeles, CA, United States, ⁶University of Minnesota, Twin Cities, MN, United States

Introduction

AMG 386 is a peptide-fc fusion protein (peptibody) that specifically inhibits the interaction of angiopoietins-1 and -2 (Ang1/2) with Tie-2 receptor (1). In a preclinical setting, angiopoietin inhibitors have been shown to suppress Colo205 tumor xenograft growth (with an associated increase in necrotic tumor fraction) and VEGF-induced corneal angiogenesis (1). We performed DCE-MRI in Colo205 xenografts and in the first in human (FIH) clinical trial (2) to study the effect of AMG 386 on tumor vasculature.

Materials & Methods

Preclinical: An MRI study was performed on anesthetized Colo205 xenograft - CD 1 nu/nu mice using a 4.7 T Bruker BioSpec. DCE-MRI with gadopentetate dimeglumine (GD, 0.2 mmol/kg i.v.) was used to assess tumor vascularity (3) and retention of a novel biodegradable polyglutamic acid Gd-DTPA polymer (PG, 0.3 mmol/kg i.v.) was used to assess tumor necrosis (4) [only DCE-MRI data are reported here]. DCE-MRI (8 slices, TE=1.4 ms, TR=40 ms, $\alpha=35^\circ$, 5 sec per acquisition) was performed at baseline and 7 days after treatment in six vehicle control animals and six treatment animals, at each of four dose levels (0.56, 2.8, 14, and 350 μ g AMG 386 s.c. twice weekly). GD was administered 5 min following injection of PG, which saturated the blood pool signal. In order to more closely mimic the clinical setting, a second study was performed using GD only to acquire DCE-MRI without prior injection of PG at baseline and 7 days after treatment in six vehicle control animals and six 350 μ g AMG 386 treated animals. DCE-MRI data were analyzed as previously described (3) to determine the muscle normalized initial area under the curve (IAUC). T-tests were used to test whether a mean differed from zero (paired) or differed between two groups.

FIH clinical: Four-six subjects in 5 sequential dose escalation cohorts received weekly IV doses of AMG 386 at 0.3, 1, 3, 10, and 30 mg/kg and ten subjects in a dose expansion cohort received weekly IV doses of 30 mg/kg AMG 386. Three-dimensional oblique coronal gradient echo image DCE-MRI (12 slices (8 used), TE=1.1 ms, TR=5.3 ms, $\alpha=30^\circ$, 11 sec per acquisition) was performed at 1.5 T at baseline, day 2, and week 4 (escalation cohorts) or week 8 (expansion cohort) for 17 of the 32 subjects entered into the study. DCE-MRI data were analyzed as previously described (5) to determine the blood normalized IAUC and K^{trans} . Since multiple tumors were assessed in some subjects, a mixed model with subject as a random effect was used to estimate the mean percent change in median IAUC and the standard error (SE) from baseline to both day 2 and week 8.

Results & Discussion

Preclinical: Figure 1 shows the percent changes in tumor IAUC (normalized to the same measure in muscle) at Day 7 compared to baseline. The mean (\pm SE) change in IAUC was $-2.2\% \pm 11.5\%$ for control mice (N=12; P=0.85) and $-25.1\% \pm 3.8\%$ for treated mice (N=28; P<0.001), no dose-response relationship was evident. For mice treated with 350 μ g AMG 386, there is no difference between the change in IAUC when both contrast agents were used and when only GD was used (P=0.45). This indicates that clinically-available low MW contrast agent should be able to assess the vascular effect of angiopoietin-targeted agents in clinical trials. It should be noted that the treatment effect is substantially less than that previously reported for VEGF-targeted agents.

FIH clinical: A $\geq 20\%$ reduction from baseline in median IAUC (normalized to the same measure in blood) was observed in 8 of 15 evaluable lesions (6 of 12 subjects) 48 hours after the first dose of AMG 386, in 2 of 5 lesions (2 of 5 subjects) at week 4, and in 5 of 8 evaluable lesions (4 of 7 subjects) at week 8 (Figure 2). No exposure response relationship was evident; 13 of 17 subjects studied by DCE-MRI (including 10 of 12 subjects with analyzable DCE-MRI data) received the highest dose of AMG 386 (30 mg/kg). The mean (\pm SE) change in median IAUC for subjects treated with 30 mg/kg AMG 386 was $-19.4\% \pm 7.1\%$ two days after the start of treatment (N=10; P=0.023) and $-28.9\% \pm 10.5\%$ eight weeks after the start of treatment (N=6; P=0.040). The changes in K^{trans} data are similar to those in IAUC, which are consistent with the changes observed in the preclinical study.




Figure 1 Mean %change in IAUC in Colo205 tumors at Day 7 following treatment with AMG 386. Solid circles represent the study using both contrast agents; open squares represent the GD only group. (Error bars = SE)




Figure 2 'Waterfall' bar graph showing %change in median IAUC at 48 h (blue), week 4 (red) and week 8 (black) after AMG 386 treatment in the FIH study. The change was 0% for the first tumor at Week 4 and for the third tumor at 48 h.

Conclusion

Even though the vascular effects are not as dramatic as for VEGF-targeted molecules, both pre-clinical and clinical DCE-MRI results demonstrate a significant vascular effect of this first-in-class anti-angiogenic investigational drug that provides highly potent and selective inhibition of angiopoietins (1).

References

1. J Oliner et al. Cancer Cell 2004;6(5):507-516.
2. L Rosen et al. ASCO, 2007; 3522.
3. JL Evelhoch et al. Clin Cancer Res 2004;10(11):3650-3657.
4. EF Jackson et al. Int J Radiat Oncol Biol Phys 2007;68(3):830-838.
5. G Liu et al. J Clin Oncol 2005;23(24):5464-5473.